Waldenströ m's macroglobulinemia (WM), or macroglobulinemic lymphoma, is a generalized chronic lymphoproliferative disorder characterized by the production of a monoclonal immunoglobulin M (IgM) by well-differentiated plasmacytic lymphocytes. Clinical features include hyperviscosity syndrome, anemia, peripheral neuropathy, organ enlargement and monoclonal blood lymphocytosis. 1 Long-term therapy usually consists of low-dose chlorambucil, although both daily low-dose schedules and intermittent high-dose schedules have been used. 2 There is increasing evidence that the purine analogs fludarabine (FDR) and cladribine (2-chlorodeoxyadenosine, 2-CdA), which are active in low-grade lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and low-grade lymphomas, are also active in WM patients resistant to alkylating agents. Purine analogs may yield higher response rates when used as first-line therapy. [3] [4] [5] The combination of FDR with cyclophosphamide (Cy) gives an 80% response rate in untreated indolent malignancies such as CLL 6, 7 and a 30% response rate in previously treated patients. 8 Recently, the German CLL group reported a better response rate and response duration in patients treated with FDR plus Cy than in those treated with FDR alone in a randomized phase III study. 9 We report the activity and toxicity of the FDR/Cy combination in 49 patients with WM treated from 2000 to 2003.
Patients and methods
From January 2000 to 2003, 49 patients who met the following criteria, based on the second Waldenströ m workshop recommendations, were included in this retrospective study: WM with infiltration by well-differentiated lymphocytes and atypical or lymphocytic plasma cells in biopsy samples from involved organs, and a monoclonal IgM component on immunoelectrophoresis. 10 The characteristics of the patients are summarized in Table 1 . Median age was 64 years (range 54-83 years). The median time from diagnosis to the beginning of FDR/Cy therapy was 26 months (range 0-183 months). Prior to FDR/Cy initiation, the median IgM level measured by electrophoresis was 24.7 g/l (range 2-71.3 g/l), the median hemoglobin level was 9.9 g/dl (4.6-14.9 g/dl), the median albumin level was 39.5 g/l (23-60.2 g/l), and the median beta 2 microglobulin level was 3 mg/l (1.4-7.6 mg/l).
A total of 35 patients had previously been treated, with more than one line of chemotherapy in 13 cases. In all, 14 patients had never been treated. FDR and Cy were given at respective doses of 30 and 300 mg/m 2 IV, daily for three consecutive days (45 patients), or 30 and 200 mg/m 2 by mouth, daily for five consecutive days (four patients). Courses were repeated every 4 weeks until a maximum response was achieved, provided the white blood cell count recovered to 2.5 Â 10 3 /ml and the platelet count to 100 Â 10 3 /ml (unless low values were attributed to extensive marrow infiltration by lymphocytes). Oral trimethoprim-sulfamethoxazole (200-40 mg/day) or pentamidine aerosols (300 mg once a month) and oral valaciclovir (500 mg/day) were used to prevent Pneumocystis carinii and herpes virus infections, respectively, during treatment. The response criteria were those agreed at the second Waldenströ m workshop.
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Partial responses were defined as a sustained fall of more than 50% in the IgM production rate (electrophoresis), on at least two occasions 2 months apart, with more than a 50% reduction in the size of all other involved organs. Complete responses were defined as a disappearance of the monoclonal protein (immunofixation), resolution of lymphadenopathy and splenomegaly, and less than 20% of lymphocytes in bone marrow. Responding patients were monitored without treatment until disease progression, defined as a more than 25% increase in tumor mass relative to the lowest level achieved. Treatment was considered to have failed in patients with a mixed response or no response. Responses were evaluated after the third cycle and at treatment discontinuation. Tumor masses were assessed by computed tomographic scan of the chest, abdomen and pelvis, with measurement of all involved lymph nodes, liver and spleen sizes before and at treatment discontinuation. Adverse effects and toxicity were analyzed according to World Health Organization criteria.
Statistical analysis
The cutoff date for this analysis was March 1 2004. Event-free survival (EFS) was measured from enrollment to disease progression, death from any cause, or the last follow-up visit. The time to treatment failure was measured from the date of response to disease progression or death, in responding patients only. Overall survival (OS) was measured from enrollment to death or the last follow-up visit. Groups were compared with Fisher's exact test and the Wilcoxon test. Survival curves were plotted by using the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox regression modeling was used to identify a set of prognostic variables, namely age (o and 465 years) hemoglobin (o and 412 g/ml and 10 g/100 ml), beta2 microglobulin (o and 43 mg/l) IgM (o and 420 and 40 g/l) and sex. 12, 13 All analyses were performed with Splus software (Mathsoft, Seattle, WA, USA).
Results

Responses and survival
A total of 49 patients received the first cycle of FDR/Cy and 48 patients received two or more courses. A median of four courses of FDR/Cy were administered (range 1-6 courses). In all, 38 patients (77.6%) patients had a partial response, and treatment failed in the remaining 11 patients (nine patients had stable disease and two patients had progressive disease). In all, 13 patients had nodal or spleen involvement before starting the treatment. All patients with a partial response on the immunoglobulin measurement (11/13) had a tumor reduction 450%. There were not discrepancies regarding the IgM reduction and the tumor masses reduction There were no differences statistically significant regarding the response rate in untreated patients (12/14; 85%) and in previously treated patients (24/35; 70%). Nine patients had a reduction of more than 75% in the monoclonal component but none of the patients was in complete response. In all, 12 patients died, four from progression, one from a high-grade lymphoma, four from a second malignancy (acute myeloid leukemia in two cases; prostate cancer and melanoma in one case each). Three patients died of infections during treatment; two of these patients were in partial response. In all, 37 patients are alive, 32 in response and five in failure or relapse.
The following parameters had no influence on the response to FDR/Cy: age, gender, anemia, albumin, beta 2 microglobulin, and the level of the monoclonal component. In multivariate analysis, age below 65 years and a monoclonal component above 40 g/l positively influenced the event-free and OS rates (Table 2) . With a median follow-up of of 25 months for patients still alive at the cutoff date, six patients have relapsed and two patients have developed a diffuse large-cell lymphoma. The median time to treatment failure was 27 months. The median EFS time is 27 months and the median survival time has not been reached (Figures 1 and 2 ).
Adverse effects
Hematologic toxicity was the main source of adverse effects, with 20 episodes of Xgrade 3 neutropenia, four episodes of Xgrade 3 anemia and 14 episodes of Xgrade 3 thrombocytopenia (ECOG definitions). Four patients developed a grade X3 infections: one patient who did not receive specific prophylaxis developed P. carinii pneumonia which required chemotherapy to be discontinued, two patients developed pneumonia, one patient developed infectious spondylodiscitis, and one patient a septic shock. Three of them died: two of pneumonia, one of septic shock. One patient developed FDR-related autoimmune hemolytic anemia after the third cycle.
Discussion
Despite the introduction of multiple chemotherapy regimens for the treatment of low-grade malignancies over the last three decades, there has been no marked improvement in OS. The standard therapy of WM is based on alkylating agents, with or without glucocorticoids. These treatments induce responses in about one-half of previously untreated patients, with a median survival time of about 5 years. 1,2 Nucleoside analogs have also been used in WM. In a phase II trial of FDR as initial therapy for WM, the overall response rate was 38% (complete remissions in 3%) among 118 patients receiving four cycles of FDR at a dose of 30 mg/m 2 i.v. daily for five consecutive days, followed by a further four cycles in responding patients. 5 The 5-year rates of OS and progression-free survival (PFS) were 62 and 49%, respectively. FDR induces responses in about one-third of patients who were resistant to a previous treatment. A multicenter randomized study comparing FDR with the Cy/doxorubicin/prednisolone (CAP) combination in 92 patients in first relapse or with primary refractory disease following treatment with alkylating agents showed a higher response rate in the FDR arm (30 vs 11%) and also more durable responses (19 vs 3 months).
14 A benefit was also found with FDR in terms of quality-adjusted survival, although there was no difference in the overall median survival time. 15 Adding a DNA-damaging agent -Cy -to FDR may enhance the activity of the nucleoside analog. 16 Several investigators have observed enhanced activity of a purine nucleoside analog combined with a DNA-damaging agent in vitro.
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Several trials have examined combinations of nucleoside analogs with alkylating agents in low-grade lymphoid malignancies, 6, 7 obtaining a CR rate of 50% in previously treated and untreated patients with CLL. In WM, one author reported a 55% response rate and a median time to progression of 24 months in 11 poor-prognosis patients. 18 The results of this regimen in patients with macroglobulinemia are quite encouraging. The immunosuppression induced by purine nucleoside analogs is well known, and causes a lengthy fall in CD4
þ and CD8 þ cell counts, contributing to a variety of opportunistic infections and raising the possibility that routine prophylaxis of opportunistic infections might be warranted in patients having previously received intensive therapy. 19 In our study, three highly previously treated patients died from infections. Following studies of nucleoside analog combinations, close attention was paid to supportive care, including hematopoietic support with growth factors and the use of Pneumocystic carinii prophylaxis.
Interestingly, factors negatively influencing EFS and OS were age over 65 years and IgM levels below 40 g/l. Age had a poor prognostic significance in most studies. [19] [20] [21] [22] [23] [24] Indeed, a large proportion of patients die from unrelated causes because of their advanced age at diagnosis. Several studies have shown a negative prognostic influence of high monoclonal IgM levels 22, 25 but Dhodapkhar et al 5, 26 found that patients with a low monoclonal concentration and a high beta 2 microglobulin had poor outcomes. We did not confirm the other prognostic factors described in the literature, such as high beta 2 microglubulin levels, low albumin levels, anemia or thrombopenia but our series is quite small and the FDR-Cy combination may modified the prognostic factors.
As in other indolent lymphoproliferative diseases resistant to FDR, more intensive treatment with myeloablative therapy and peripheral blood stem cell (PBSC) transplantation, as used for lymphoma, might be offered to those patients who qualify. 27 A negative impact of FDR on further PBSC mobilization is suspected, but the underlying mechanism is unclear. 28 In a prospective phase II study of 38 patients with CLL, who received 6 monthly courses of FDR (30 mg/m 2 /day) plus Cy (200 mg/m 2 / day), both given orally for five consecutive days, steady-state filgrastim-or lenograstim-primed PBSC mobilization was unsuccessful in 32 patients. This implies that the use of stemcell-damaging agents should be reconsidered in treatment strategies including high-dose therapy and autologous stem cell transplantation. In our study, PBSC mobilization was unsuccessful in four cases and successful in two. Two patients received autologous PBSC transplantation, but with a graft collected before FDR-Cy administration, while one patient received allogeneic PBSC from an unrelated donor.
This retrospective study and other published data suggest that nucleoside analog-Cy combination therapy, which gives a response rate of 75% in patients with WM, could be offered both to patients in relapse and as front-line therapy in prospective trials. Autologous stem cell transplantation may be an option for younger patients, but graft collection should be done before starting treatment. Overall survival of the 49 patients.
Figure 2
Time to treatment failure of the 38 responding patients.
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